Neurocrine Biosciences, Inc. $NBIX Stock Sold by GW&K Investment Management LLC

GW&K Investment Management LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the third quarter, HoldingsChannel reports. The institutional investor owned 557,733 shares of the company’s stock after selling 9,688 shares during the quarter. GW&K Investment Management LLC’s holdings in Neurocrine Biosciences were worth $79,109,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Neurocrine Biosciences during the second quarter worth about $2,310,886,000. Renaissance Technologies LLC raised its holdings in shares of Neurocrine Biosciences by 8.0% in the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after acquiring an additional 180,100 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of Neurocrine Biosciences by 5,055.5% in the 3rd quarter. Aberdeen Group plc now owns 1,183,444 shares of the company’s stock valued at $167,860,000 after acquiring an additional 1,160,489 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Neurocrine Biosciences by 97.0% during the 1st quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after acquiring an additional 472,408 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at about $117,827,000. Institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on NBIX shares. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Stifel Nicolaus lifted their target price on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Mizuho upgraded shares of Neurocrine Biosciences to a “hold” rating in a research report on Wednesday, September 16th. Citigroup lifted their price objective on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Finally, Cantor Fitzgerald upped their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $202.59.

Read Our Latest Research Report on Neurocrine Biosciences

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 2,311 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the sale, the chief financial officer directly owned 42,808 shares of the company’s stock, valued at $6,729,417.60. The trade was a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,500 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $145.79, for a total transaction of $1,093,425.00. Following the sale, the director owned 10,386 shares of the company’s stock, valued at approximately $1,514,174.94. The trade was a 41.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 18,137 shares of company stock valued at $2,829,332. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $156.59 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $186.12. The stock has a 50 day simple moving average of $149.14 and a two-hundred day simple moving average of $149.43. The firm has a market cap of $15.85 billion, a P/E ratio of 20.41, a P/E/G ratio of 0.66 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. The business’s revenue was up 41.3% compared to the same quarter last year. During the same period last year, the firm posted $2.04 earnings per share. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 8.41 earnings per share for the current year.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.

Further Reading

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.